Harmony Biosciences (HRMY) 2024 Wells Fargo Healthcare Conference summary

Company overview and growth drivers

• Seven years into operations, focusing on expanding a late-stage pipeline with three orphan rare CNS franchises and a strong commercial base in sleep/wake disorders.

• WAKIX, a non-scheduled treatment for narcolepsy, has achieved a successful launch and is on track for over $1 billion in annual revenue.

• Pipeline includes neurobehavioral and rare epilepsy franchises, each with potential peak sales of $1–2 billion.

• Eight assets across 13 development programs, with three in phase 3 and a fourth starting soon; aiming for one new product or indication launch annually for the next five years.

• Strong cash position and profitability support ongoing pipeline expansion and acquisitions.

Clinical development and regulatory updates

• Recent pediatric narcolepsy approval expands market reach.

• Phase 3 trial in idiopathic hypersomnia (IH) showed strong open-label response but missed primary endpoint in randomized withdrawal, likely due to placebo effect.

• Over 90% of IH trial patients entered open-label extension, providing long-term safety and effectiveness data.

• sNDA submission for IH on track for Q4, leveraging totality of evidence, including real-world European data and regulatory flexibility due to unmet need.

• WAKIX offers once-daily, non-scheduled dosing, addressing limitations of current IH treatments.

Commercial performance and market opportunity

• Narcolepsy market in the U.S. includes about 80,000 diagnosed patients, with WAKIX approaching 7,000 treated by year-end.

• IH market estimated at 80,000 patients, with 40,000 diagnosed; potential market opportunity exceeds $500 million.

• Q2 sales reached $172.8 million, nearly 30% growth year-over-year; full-year guidance reiterated at $700–$720 million.

• Recent pediatric launch and broad prescriber base support continued growth.

• Polypharmacy in narcolepsy and a unique product profile drive broad clinical utility and market penetration.